<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348165</url>
  </required_header>
  <id_info>
    <org_study_id>1306.1</org_study_id>
    <secondary_id>2010-023462-52</secondary_id>
    <nct_id>NCT01348165</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers</brief_title>
  <official_title>Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers (A Randomised, Single-blind, Placebo-controlled Phase I Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy
      Male Volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As a transition from preclinical investigations to clinical development in this first-in-man
      trial, safety, tolerability, and pharmacokinetics of BI 137882 will be assessed in healthy
      male volunteers using single rising oral doses in order to provide the basis for a potential
      ongoing clinical development of BI 137882 in the indication of COPD.

      Healthy male subjects aged 21 - 50 years will be recruited for this study. They provide a
      relatively stable physiological, biochemical and hormonal basis (steady state) for studying
      drug effects, they show no disease-related variation and they are not taking concomitant
      medication.

      Within each dose group, all actively treated individuals will receive the same BI 137882
      dose. The next higher dose will only be administered if the treatment in the preceding dose
      group was safe and well tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>May 2011</start_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects With Drug Related Adverse Events</measure>
    <time_frame>From baseline up to 28 days</time_frame>
    <description>Number of subjects with drug related adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change from baseline for systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse Rate (PR)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change from Baseline to 28 Days in Pulse Rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory Rate (RR)</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change from Baseline to 28 Days in Respiratory rate (RR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body Temperature</measure>
    <time_frame>Baseline and 28 days</time_frame>
    <description>Change from baseline to 28 Days in Body temperature</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Tolerability by Investigator</measure>
    <time_frame>28 days</time_frame>
    <description>The investigator assessed tolerability based on adverse events and the laboratory evaluation according to the categories 'good', 'satisfactory', 'not satisfactory', and 'bad'.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Measured Concentration (Cmax)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Maximum measured concentration of BI 137882 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Measured Concentration (Tmax)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Time from dosing to maximum measured concentration of the analyte in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to Infinity (AUC0-infinity)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Area under the concentration-time curve of BI 137882 in plasma over the time interval from 0 extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Terminal half-life of BI 137882 in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Rate Constant (λz)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Terminal rate constant in plasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Residence Time (MRTpo)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Mean residence time of the analyte in the body after oral administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Clearance (CL/F)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Apparent clearance of the analyte in plasma after extravascular administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
    <description>Apparent volume of distribution of the analyte during the terminal phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of BI 137882 Eliminated in Urine From the Time Point t1 to Time Point t2</measure>
    <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
    <description>Amount of BI 137882 eliminated in urine from the time point t1 to time point t2 (Aet1-t2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction of BI 137882 Eliminated in Urine From Time Point t1 to Time Point t2</measure>
    <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
    <description>Fraction of BI 137882 eliminated in urine from time point t1 to time point t2 (fet1-t2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance of BI 137882 From the Time Point t1 Until the Time Point t2</measure>
    <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
    <description>Renal clearance of BI 137882 from the time point t1 until the time point t2 (CLR,t1-t2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Tumour Necrosis Factor-alpha (TNF-α) Induced by Lipopolysaccharide (LPS) in Whole Blood ex Vivo</measure>
    <time_frame>0.5 hours (h) before drug administration and 2h, 6h, 24h and 48h after drug administration</time_frame>
    <description>Concentrations of TNF-α in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Concentrations of TNF-α in blood drawn after treatment with BI 137882 were compared with those in pre-dose samples to calculate the percent of inhibition of LPS induction of TNF-α production. Results indicate percent change from baseline of LPS-induced TNF-α production. A positive value indicates inhibition of the production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Leukotriene B4 (LTB4) Induced by N-formyl-methionine-leucine-phenylalanine (fMLP) in Whole Blood ex Vivo.</measure>
    <time_frame>0.5 hours (h) before drug administration and 2h, 6h, 24h and 48h after drug administration</time_frame>
    <description>Percent of inhibition of fMLP induction of LTB4 production. Concentrations of LTB4 in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Results indicate percent change from baseline of fMLP induction of LTB4 production. A positive value indicates inhibition of the production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Effect Curve (AUEC)</measure>
    <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
    <description>Area under the effect curve for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Effect (Emax)</measure>
    <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
    <description>Maximum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Effect (Emin)</measure>
    <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
    <description>Minimum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BI 137882 Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BI 137882 Dose 9</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Powder for oral solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 137882</intervention_name>
    <description>Powder for oral solution</description>
    <arm_group_label>BI 137882 Dose 1</arm_group_label>
    <arm_group_label>BI 137882 Dose 2</arm_group_label>
    <arm_group_label>BI 137882 Dose 3</arm_group_label>
    <arm_group_label>BI 137882 Dose 4</arm_group_label>
    <arm_group_label>BI 137882 Dose 5</arm_group_label>
    <arm_group_label>BI 137882 Dose 6</arm_group_label>
    <arm_group_label>BI 137882 Dose 7</arm_group_label>
    <arm_group_label>BI 137882 Dose 8</arm_group_label>
    <arm_group_label>BI 137882 Dose 9</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powder for oral solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Healthy males according to the following criteria: Based upon a complete medical
             history, including the physical examination, vital signs (blood pressure (BP), pulse
             rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests

          2. Age 21 to 50 years

          3. BMI 18.5 to 29.9 kg/m2 (Body Mass Index)

          4. Signed and dated written informed consent prior to admission to the study in
             accordance with GCP and the local legislation.

        Exclusion criteria:

          1. Any finding of the medical examination (including BP, PR and ECG) deviating from
             normal and of clinical relevance

          2. Any evidence of a clinically relevant concomitant disease

          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          4. Surgery of the gastrointestinal tract (except appendectomy)

          5. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          6. History of relevant orthostatic hypotension, fainting spells or blackouts.

          7. Chronic or relevant acute infections

          8. History of relevant allergy/hypersensitivity (including allergy to drug or its
             excipients)

          9. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

         10. Use of drugs which might reasonably influence the results of the trial or that prolong
             the QT/QTc interval based on the knowledge at the time of protocol preparation within
             10 days prior to administration or during the trial

         11. Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

         12. Smoker (more than 10 cigarettes /day)

         13. Inability to refrain from smoking on trial days

         14. Alcohol abuse (more than 20 g/day)

         15. Drug abuse

         16. Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

         17. Excessive physical activities (within one week prior to administration or during the
             trial)

         18. Any laboratory value outside the reference range that is of clinical relevance

         19. Inability to comply with dietary regimen of trial site

         20. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval &gt;450 ms);

         21. A history of additional risk factors for Torsades de points (TdP) (e.g., heart
             failure, hypokalemia, family history of Long QT Syndrome)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <results_first_submitted>March 12, 2014</results_first_submitted>
  <results_first_submitted_qc>May 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 4, 2014</results_first_posted>
  <last_update_submitted>August 4, 2016</last_update_submitted>
  <last_update_submitted_qc>August 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>A solution of 0.7% sodium dodecyl sulphate (SDS) and volume depends on corresponding dose group</description>
        </group>
        <group group_id="P2">
          <title>0.01 mg</title>
          <description>BI 137882 with 0.01 mg Dose level</description>
        </group>
        <group group_id="P3">
          <title>0.03 mg</title>
          <description>BI 137882 with 0.03 mg Dose level</description>
        </group>
        <group group_id="P4">
          <title>0.1 mg</title>
          <description>BI 137882 with 0.1 mg Dose level</description>
        </group>
        <group group_id="P5">
          <title>0.25 mg</title>
          <description>BI 137882 with 0.25 mg Dose level</description>
        </group>
        <group group_id="P6">
          <title>0.5 mg</title>
          <description>BI 137882 with 0.5 mg Dose level</description>
        </group>
        <group group_id="P7">
          <title>0.6 mg</title>
          <description>BI 137882 with 0.6 mg Dose level</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated Set which included all subjects who received one dose of trial medication</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
        </group>
        <group group_id="B2">
          <title>0.01 mg</title>
          <description>BI 137882 with 0.01 mg Dose level</description>
        </group>
        <group group_id="B3">
          <title>0.03 mg</title>
          <description>BI 137882 with 0.03 mg Dose level</description>
        </group>
        <group group_id="B4">
          <title>0.1 mg</title>
          <description>BI 137882 with 0.1 mg Dose level</description>
        </group>
        <group group_id="B5">
          <title>0.25 mg</title>
          <description>BI 137882 with 0.25 mg Dose level</description>
        </group>
        <group group_id="B6">
          <title>0.5 mg</title>
          <description>BI 137882 with 0.5 mg Dose level</description>
        </group>
        <group group_id="B7">
          <title>0.6 mg</title>
          <description>BI 137882 with 0.6 mg Dose level</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="1"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.7" spread="7.6"/>
                    <measurement group_id="B2" value="34.8" spread="10.3"/>
                    <measurement group_id="B3" value="40.8" spread="6.6"/>
                    <measurement group_id="B4" value="37.2" spread="7.1"/>
                    <measurement group_id="B5" value="36.5" spread="10.0"/>
                    <measurement group_id="B6" value="42.0">Measure of variation not applicable as only one patient in treatment group</measurement>
                    <measurement group_id="B7" value="35.5" spread="8.5"/>
                    <measurement group_id="B8" value="36.8" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking Status</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Smoked</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ex-Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Currently Smokes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alcohol Status</title>
          <description>Level of interference was based on if a subject drank alcohol to an extent that would interfere with the objectives of the trial.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Never Drinker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - no interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drinks - possible interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects With Drug Related Adverse Events</title>
        <description>Number of subjects with drug related adverse events (AEs)</description>
        <time_frame>From baseline up to 28 days</time_frame>
        <population>Treated Set which included all subjects who received one dose of trial medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Drug Related Adverse Events</title>
          <description>Number of subjects with drug related adverse events (AEs)</description>
          <population>Treated Set which included all subjects who received one dose of trial medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Blood Pressure</title>
        <description>Change from baseline for systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>Change from baseline for systolic blood pressure (SBP) and diastolic blood pressure (DBP)</description>
          <population>Treated Set</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="9.4"/>
                    <measurement group_id="O2" value="1.0" spread="3.4"/>
                    <measurement group_id="O3" value="2.8" spread="4.3"/>
                    <measurement group_id="O4" value="-3.3" spread="6.9"/>
                    <measurement group_id="O5" value="-5.8" spread="9.6"/>
                    <measurement group_id="O6" value="-16">Measure of dispersion not applicable as only one patient in this treatment group</measurement>
                    <measurement group_id="O7" value="1.4" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="3.7"/>
                    <measurement group_id="O2" value="-1.6" spread="6.8"/>
                    <measurement group_id="O3" value="-1.2" spread="2.7"/>
                    <measurement group_id="O4" value="-2.2" spread="4.2"/>
                    <measurement group_id="O5" value="-3.0" spread="3.7"/>
                    <measurement group_id="O6" value="-12.0">Measure of dispersion not applicable as only one patient in this treatment group</measurement>
                    <measurement group_id="O7" value="0.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pulse Rate (PR)</title>
        <description>Change from Baseline to 28 Days in Pulse Rate</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate (PR)</title>
          <description>Change from Baseline to 28 Days in Pulse Rate</description>
          <population>Treated Set</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="12.8"/>
                    <measurement group_id="O2" value="6.4" spread="6.3"/>
                    <measurement group_id="O3" value="6.0" spread="5.8"/>
                    <measurement group_id="O4" value="-0.7" spread="6.2"/>
                    <measurement group_id="O5" value="0.7" spread="5.2"/>
                    <measurement group_id="O6" value="3.0">Measure of dispersion not applicable as only one patient in this treatment group</measurement>
                    <measurement group_id="O7" value="0.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Respiratory Rate (RR)</title>
        <description>Change from Baseline to 28 Days in Respiratory rate (RR)</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Respiratory Rate (RR)</title>
          <description>Change from Baseline to 28 Days in Respiratory rate (RR)</description>
          <population>Treated Set</population>
          <units>breaths/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="4.6"/>
                    <measurement group_id="O2" value="1.2" spread="5.4"/>
                    <measurement group_id="O3" value="1.3" spread="1.6"/>
                    <measurement group_id="O4" value="0.5" spread="2.1"/>
                    <measurement group_id="O5" value="-1.8" spread="2.4"/>
                    <measurement group_id="O6" value="3.0">Measure of dispersion not applicable as only one patient in this treatment group</measurement>
                    <measurement group_id="O7" value="2.0" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Measured Concentration (Cmax)</title>
        <description>Maximum measured concentration of BI 137882 in plasma.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Measured Concentration (Cmax)</title>
          <description>Maximum measured concentration of BI 137882 in plasma.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="20.0"/>
                    <measurement group_id="O2" value="4.79" spread="25.6"/>
                    <measurement group_id="O3" value="11.2" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Measured Concentration (Tmax)</title>
        <description>Time from dosing to maximum measured concentration of the analyte in plasma.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Measured Concentration (Tmax)</title>
          <description>Time from dosing to maximum measured concentration of the analyte in plasma.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.99" spread="68.8" lower_limit="0.98" upper_limit="4.00"/>
                    <measurement group_id="O2" value="1.48" spread="62.9" lower_limit="0.97" upper_limit="3.98"/>
                    <measurement group_id="O3" value="0.99" spread="115" lower_limit="0.48" upper_limit="5.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve 0 to Infinity (AUC0-infinity)</title>
        <description>Area under the concentration-time curve of BI 137882 in plasma over the time interval from 0 extrapolated to infinity.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to Infinity (AUC0-infinity)</title>
          <description>Area under the concentration-time curve of BI 137882 in plasma over the time interval from 0 extrapolated to infinity.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4" spread="19.6"/>
                    <measurement group_id="O2" value="153" spread="27.3"/>
                    <measurement group_id="O3" value="392" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Half-life (t1/2)</title>
        <description>Terminal half-life of BI 137882 in plasma.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Half-life (t1/2)</title>
          <description>Terminal half-life of BI 137882 in plasma.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.8" spread="17.7"/>
                    <measurement group_id="O2" value="35.8" spread="46.8"/>
                    <measurement group_id="O3" value="37.2" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
        <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve 0 to the Last Quantifiable Data Point (AUC0-tz)</title>
          <description>Area under the concentration-time curve of the analyte in plasma over the time interval from 0 up to the last quantifiable data point.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>nmol*h/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="35.9"/>
                    <measurement group_id="O2" value="111" spread="27.5"/>
                    <measurement group_id="O3" value="348" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Terminal Rate Constant (λz)</title>
        <description>Terminal rate constant in plasma.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Terminal Rate Constant (λz)</title>
          <description>Terminal rate constant in plasma.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>1/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0304" spread="17.7"/>
                    <measurement group_id="O2" value="0.0194" spread="46.8"/>
                    <measurement group_id="O3" value="0.0186" spread="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Residence Time (MRTpo)</title>
        <description>Mean residence time of the analyte in the body after oral administration.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Residence Time (MRTpo)</title>
          <description>Mean residence time of the analyte in the body after oral administration.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" spread="16.5"/>
                    <measurement group_id="O2" value="49.6" spread="41.1"/>
                    <measurement group_id="O3" value="52.8" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Clearance (CL/F)</title>
        <description>Apparent clearance of the analyte in plasma after extravascular administration.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Clearance (CL/F)</title>
          <description>Apparent clearance of the analyte in plasma after extravascular administration.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>mL/min</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.8" spread="19.6"/>
                    <measurement group_id="O2" value="58.7" spread="27.3"/>
                    <measurement group_id="O3" value="55.1" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vz/F)</title>
        <description>Apparent volume of distribution of the analyte during the terminal phase.</description>
        <time_frame>30 minutes (min) before drug administration and 30min, 1 hour (h), 2h, 4h, 6h, 8h, 12h, 24h, 34h, 48h, 72h, 96h, 144h, 192h, 264h, 336h and 480h after drug administration</time_frame>
        <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O2">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vz/F)</title>
          <description>Apparent volume of distribution of the analyte during the terminal phase.</description>
          <population>Treated Set. Descriptive statistics are only presented for treatment groups where the summary statistics were calculated.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="195" spread="11.5"/>
                    <measurement group_id="O2" value="182" spread="28.2"/>
                    <measurement group_id="O3" value="177" spread="9.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of BI 137882 Eliminated in Urine From the Time Point t1 to Time Point t2</title>
        <description>Amount of BI 137882 eliminated in urine from the time point t1 to time point t2 (Aet1-t2)</description>
        <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
        <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of BI 137882 Eliminated in Urine From the Time Point t1 to Time Point t2</title>
          <description>Amount of BI 137882 eliminated in urine from the time point t1 to time point t2 (Aet1-t2)</description>
          <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fraction of BI 137882 Eliminated in Urine From Time Point t1 to Time Point t2</title>
        <description>Fraction of BI 137882 eliminated in urine from time point t1 to time point t2 (fet1-t2)</description>
        <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
        <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Fraction of BI 137882 Eliminated in Urine From Time Point t1 to Time Point t2</title>
          <description>Fraction of BI 137882 eliminated in urine from time point t1 to time point t2 (fet1-t2)</description>
          <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance of BI 137882 From the Time Point t1 Until the Time Point t2</title>
        <description>Renal clearance of BI 137882 from the time point t1 until the time point t2 (CLR,t1-t2)</description>
        <time_frame>0-4, 4-8, 8-12, and 12-24 hours after drug administration</time_frame>
        <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance of BI 137882 From the Time Point t1 Until the Time Point t2</title>
          <description>Renal clearance of BI 137882 from the time point t1 until the time point t2 (CLR,t1-t2)</description>
          <population>There was no measurable BI 137882 excreted in urine so this pharmacokinetic parameter was not calculated.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Tumour Necrosis Factor-alpha (TNF-α) Induced by Lipopolysaccharide (LPS) in Whole Blood ex Vivo</title>
        <description>Concentrations of TNF-α in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Concentrations of TNF-α in blood drawn after treatment with BI 137882 were compared with those in pre-dose samples to calculate the percent of inhibition of LPS induction of TNF-α production. Results indicate percent change from baseline of LPS-induced TNF-α production. A positive value indicates inhibition of the production.</description>
        <time_frame>0.5 hours (h) before drug administration and 2h, 6h, 24h and 48h after drug administration</time_frame>
        <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Tumour Necrosis Factor-alpha (TNF-α) Induced by Lipopolysaccharide (LPS) in Whole Blood ex Vivo</title>
          <description>Concentrations of TNF-α in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Concentrations of TNF-α in blood drawn after treatment with BI 137882 were compared with those in pre-dose samples to calculate the percent of inhibition of LPS induction of TNF-α production. Results indicate percent change from baseline of LPS-induced TNF-α production. A positive value indicates inhibition of the production.</description>
          <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
          <units>percentage of TNF-α production</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26.3" spread="45.0"/>
                    <measurement group_id="O2" value="-23.1" spread="35.6"/>
                    <measurement group_id="O3" value="-59.1" spread="35.9"/>
                    <measurement group_id="O4" value="-23.9" spread="24.0"/>
                    <measurement group_id="O5" value="1.13" spread="20.0"/>
                    <measurement group_id="O6" value="-0.41" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="64.5"/>
                    <measurement group_id="O2" value="37.9" spread="19.5"/>
                    <measurement group_id="O3" value="-5.29" spread="34.7"/>
                    <measurement group_id="O4" value="11.4" spread="25.3"/>
                    <measurement group_id="O5" value="-2.17" spread="60.5"/>
                    <measurement group_id="O6" value="12.8" spread="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.2" spread="41.8"/>
                    <measurement group_id="O2" value="-11.6" spread="30.3"/>
                    <measurement group_id="O3" value="2.05" spread="20.7"/>
                    <measurement group_id="O4" value="-16.4" spread="41.7"/>
                    <measurement group_id="O5" value="4.78" spread="36.5"/>
                    <measurement group_id="O6" value="-17.1" spread="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="44.3"/>
                    <measurement group_id="O2" value="-3.90" spread="56.9"/>
                    <measurement group_id="O3" value="7.49" spread="33.0"/>
                    <measurement group_id="O4" value="-61.0" spread="122"/>
                    <measurement group_id="O5" value="-0.98" spread="22.6"/>
                    <measurement group_id="O6" value="3.52" spread="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Concentration of Leukotriene B4 (LTB4) Induced by N-formyl-methionine-leucine-phenylalanine (fMLP) in Whole Blood ex Vivo.</title>
        <description>Percent of inhibition of fMLP induction of LTB4 production. Concentrations of LTB4 in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Results indicate percent change from baseline of fMLP induction of LTB4 production. A positive value indicates inhibition of the production.</description>
        <time_frame>0.5 hours (h) before drug administration and 2h, 6h, 24h and 48h after drug administration</time_frame>
        <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of Leukotriene B4 (LTB4) Induced by N-formyl-methionine-leucine-phenylalanine (fMLP) in Whole Blood ex Vivo.</title>
          <description>Percent of inhibition of fMLP induction of LTB4 production. Concentrations of LTB4 in plasma were determined by an enzyme-linked immunosorbent assay (ELISA). Results indicate percent change from baseline of fMLP induction of LTB4 production. A positive value indicates inhibition of the production.</description>
          <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
          <units>percentage of LTB4 production</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.6" spread="47.3"/>
                    <measurement group_id="O2" value="-0.83" spread="16.6"/>
                    <measurement group_id="O3" value="15.0" spread="29.8"/>
                    <measurement group_id="O4" value="11.1" spread="11.3"/>
                    <measurement group_id="O5" value="-29.6" spread="35.6"/>
                    <measurement group_id="O6" value="-74.4" spread="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="44.7"/>
                    <measurement group_id="O2" value="5.26" spread="21.4"/>
                    <measurement group_id="O3" value="22.8" spread="29.5"/>
                    <measurement group_id="O4" value="5.92" spread="15.8"/>
                    <measurement group_id="O5" value="-8.73" spread="39.3"/>
                    <measurement group_id="O6" value="-69.1" spread="74.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.2" spread="58.1"/>
                    <measurement group_id="O2" value="-19.1" spread="20.2"/>
                    <measurement group_id="O3" value="-25.3" spread="27.8"/>
                    <measurement group_id="O4" value="-12.1" spread="35.0"/>
                    <measurement group_id="O5" value="-59.4" spread="66.4"/>
                    <measurement group_id="O6" value="-61.2" spread="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>48 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-48.3" spread="89.7"/>
                    <measurement group_id="O2" value="-38.1" spread="43.8"/>
                    <measurement group_id="O3" value="-31.7" spread="23.2"/>
                    <measurement group_id="O4" value="1.11" spread="20.1"/>
                    <measurement group_id="O5" value="-41.6" spread="54.3"/>
                    <measurement group_id="O6" value="-94.2" spread="44.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Effect Curve (AUEC)</title>
        <description>Area under the effect curve for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
        <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
        <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group. Geometric mean and geometric coefficient of variation was not calculated for any parameter in any dose group in which zero or a negative value was calculated, as geometric means cannot be calculated with negative or zero values.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Effect Curve (AUEC)</title>
          <description>Area under the effect curve for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
          <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group. Geometric mean and geometric coefficient of variation was not calculated for any parameter in any dose group in which zero or a negative value was calculated, as geometric means cannot be calculated with negative or zero values.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25200" spread="85.9"/>
                    <measurement group_id="O2" value="34900" spread="221"/>
                    <measurement group_id="O3" value="10900" spread="654"/>
                    <measurement group_id="O4" value="NA">No descriptive statistics calculated</measurement>
                    <measurement group_id="O5" value="46900" spread="492"/>
                    <measurement group_id="O6" value="28700" spread="1050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>fMLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No descriptive statistics calculated</measurement>
                    <measurement group_id="O2" value="NA">No descriptive statistics calculated</measurement>
                    <measurement group_id="O3" value="25700" spread="6170"/>
                    <measurement group_id="O4" value="45100" spread="218"/>
                    <measurement group_id="O5" value="NA">No descriptive statistics calculated</measurement>
                    <measurement group_id="O6" value="NA">No descriptive statistics calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Effect (Emax)</title>
        <description>Maximum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
        <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
        <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Effect (Emax)</title>
          <description>Maximum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
          <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-alpha induced by LPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13400" spread="42.9"/>
                    <measurement group_id="O2" value="12000" spread="30.1"/>
                    <measurement group_id="O3" value="9990" spread="43.3"/>
                    <measurement group_id="O4" value="18200" spread="47.3"/>
                    <measurement group_id="O5" value="21500" spread="39.5"/>
                    <measurement group_id="O6" value="13800" spread="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTB4 induced by fMLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60400" spread="81.2"/>
                    <measurement group_id="O2" value="49400" spread="28.5"/>
                    <measurement group_id="O3" value="51300" spread="17.3"/>
                    <measurement group_id="O4" value="27800" spread="64.4"/>
                    <measurement group_id="O5" value="44800" spread="37.1"/>
                    <measurement group_id="O6" value="42100" spread="46.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Minimum Effect (Emin)</title>
        <description>Minimum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
        <time_frame>30 minutes (min) before drug administration and 2 hours (h), 6h, 24h and 48h after drug administration</time_frame>
        <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Effect (Emin)</title>
          <description>Minimum effect for TNF-alpha induced by LPS and LTB4 induced by fMLP. Results indicate percent change from baseline of TNF-α/LTB4 production. A positive value indicates inhibition of the production.</description>
          <population>Treated Set. Summary statistics were not calculated for the 0.5 mg group as there was only one patient in this group.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TNF-alpha induced by LPS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5200" spread="50.7"/>
                    <measurement group_id="O2" value="5500" spread="25.5"/>
                    <measurement group_id="O3" value="4730" spread="57.7"/>
                    <measurement group_id="O4" value="8210" spread="43.5"/>
                    <measurement group_id="O5" value="9570" spread="63.5"/>
                    <measurement group_id="O6" value="5890" spread="63.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LTB4 induced by fMLP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29000" spread="67.8"/>
                    <measurement group_id="O2" value="31100" spread="42.9"/>
                    <measurement group_id="O3" value="24000" spread="32.4"/>
                    <measurement group_id="O4" value="19000" spread="52.7"/>
                    <measurement group_id="O5" value="19500" spread="31.4"/>
                    <measurement group_id="O6" value="19900" spread="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Body Temperature</title>
        <description>Change from baseline to 28 Days in Body temperature</description>
        <time_frame>Baseline and 28 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature</title>
          <description>Change from baseline to 28 Days in Body temperature</description>
          <population>Treated Set</population>
          <units>degrees celcius</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.4"/>
                    <measurement group_id="O2" value="0.6" spread="0.4"/>
                    <measurement group_id="O3" value="-0.3" spread="0.3"/>
                    <measurement group_id="O4" value="0.1" spread="0.5"/>
                    <measurement group_id="O5" value="-0.3" spread="0.4"/>
                    <measurement group_id="O6" value="-0.1">Measure of dispersion not applicable as only one patient in this treatment group</measurement>
                    <measurement group_id="O7" value="0.2" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Assessment of Tolerability by Investigator</title>
        <description>The investigator assessed tolerability based on adverse events and the laboratory evaluation according to the categories ‘good’, ‘satisfactory’, ‘not satisfactory’, and ‘bad’.</description>
        <time_frame>28 days</time_frame>
        <population>Treated Set</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>A solution of 0.7% SDS and volume depends on corresponding dose group</description>
          </group>
          <group group_id="O2">
            <title>0.01 mg</title>
            <description>BI 137882 with 0.01 mg Dose level</description>
          </group>
          <group group_id="O3">
            <title>0.03 mg</title>
            <description>BI 137882 with 0.03 mg Dose level</description>
          </group>
          <group group_id="O4">
            <title>0.1 mg</title>
            <description>BI 137882 with 0.1 mg Dose level</description>
          </group>
          <group group_id="O5">
            <title>0.25 mg</title>
            <description>BI 137882 with 0.25 mg Dose level</description>
          </group>
          <group group_id="O6">
            <title>0.5 mg</title>
            <description>BI 137882 with 0.5 mg Dose level</description>
          </group>
          <group group_id="O7">
            <title>0.6 mg</title>
            <description>BI 137882 with 0.6 mg Dose level</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Tolerability by Investigator</title>
          <description>The investigator assessed tolerability based on adverse events and the laboratory evaluation according to the categories ‘good’, ‘satisfactory’, ‘not satisfactory’, and ‘bad’.</description>
          <population>Treated Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="1"/>
                <count group_id="O7" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not satisfactory</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bad</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not assessable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Until 5 days after drug administration</time_frame>
      <desc>Treatment emergent adverse events are presented, this excludes screening period and post treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>A solution of 0.7% sodium dodecyl sulphate (SDS) and volume depends on corresponding dose group</description>
        </group>
        <group group_id="E2">
          <title>0.01 mg</title>
          <description>BI 137882 with 0.01 mg Dose level</description>
        </group>
        <group group_id="E3">
          <title>0.03 mg</title>
          <description>BI 137882 with 0.03 mg Dose level</description>
        </group>
        <group group_id="E4">
          <title>0.1 mg</title>
          <description>BI 137882 with 0.1 mg Dose level</description>
        </group>
        <group group_id="E5">
          <title>0.25 mg</title>
          <description>BI 137882 with 0.25 mg Dose level</description>
        </group>
        <group group_id="E6">
          <title>0.5 mg</title>
          <description>BI 137882 with 0.5 mg Dose level</description>
        </group>
        <group group_id="E7">
          <title>0.6 mg</title>
          <description>BI 137882 with 0.6 mg Dose level</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was put on hold due to a serious adverse event (post-treatment period) which was evaluated to be not drug related and the trial was subsequently terminated.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

